Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-06-06
DOI
10.3389/fonc.2017.00114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy
- (2017) Kevin G. Shim et al. MOLECULAR THERAPY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract 4875: Developing tumor-localized, combination immunotherapies
- (2016) Brian R. Champion et al. CANCER RESEARCH
- Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
- (2016) K. A. Lawson et al. CLINICAL CANCER RESEARCH
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
- (2016) Karishma Rajani et al. MOLECULAR THERAPY
- Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
- (2016) Antonio Marchini et al. Viruses-Basel
- Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
- (2016) Tuuli Ranki et al. Journal for ImmunoTherapy of Cancer
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
- (2015) Se Hoon Park et al. MOLECULAR THERAPY
- Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients
- (2015) Timothy P Cripe et al. MOLECULAR THERAPY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report
- (2015) E . Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- Trial Watch—Oncolytic viruses and cancer therapy
- (2015) Jonathan Pol et al. OncoImmunology
- Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors
- (2014) V. Roulstone et al. CLINICAL CANCER RESEARCH
- Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF
- (2014) Weizhou Hou et al. INTERNATIONAL JOURNAL OF CANCER
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination
- (2014) Audry Fernández et al. Human Vaccines & Immunotherapeutics
- Oncolytic viruses as therapeutic cancer vaccines
- (2013) David L Bartlett et al. Molecular Cancer
- HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
- (2013) Byram W Bridle et al. MOLECULAR THERAPY
- Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy
- (2013) Babal K Jha et al. MOLECULAR THERAPY
- Maraba Virus as a Potent Oncolytic Vaccine Vector
- (2013) Jonathan G Pol et al. MOLECULAR THERAPY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans
- (2013) M. K. Kim et al. Science Translational Medicine
- Oncolytic virus therapy for cancer: the first wave of translational clinical trials
- (2013) Manish R. Patel et al. Translational Research
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer
- (2012) Lauren J. Bayne et al. CANCER CELL
- Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer
- (2012) D. M. Rommelfanger et al. CANCER RESEARCH
- Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses
- (2012) K-W Peng et al. GENE THERAPY
- Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
- (2012) Jose Pulido et al. NATURE BIOTECHNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features
- (2011) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
- (2011) Benedetto Farsaci et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of RNase L and RNA-dependent Protein Kinase (PKR) by Sunitinib Impairs Antiviral Innate Immunity
- (2011) Babal Kant Jha et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
- (2011) Tae-Ho Hwang et al. MOLECULAR THERAPY
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
- (2011) Caroline J. Breitbach et al. NATURE
- Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
- (2011) A. J. Christiansen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
- (2011) Antonella Sistigu et al. Seminars in Immunopathology
- Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
- (2010) Vincenzo Cerullo et al. CANCER RESEARCH
- Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics
- (2010) G Ungerechts et al. GENE THERAPY
- Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus
- (2010) Jan Brun et al. MOLECULAR THERAPY
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide
- (2009) X. Q. Lun et al. CLINICAL CANCER RESEARCH
- Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
- (2009) T. Kottke et al. CLINICAL CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus
- (2009) Byram W Bridle et al. MOLECULAR THERAPY
- Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
- (2008) J. Qiao et al. CLINICAL CANCER RESEARCH
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
- (2008) Byeong-Ho Park et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started